We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+29.52%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.72B
AUM Growth
+$775M
Cap. Flow
-$10.2M
Cap. Flow %
-0.22%
Top 10 Hldgs %
24.37%
Holding
169
New
21
Increased
56
Reduced
46
Closed
14

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$54.7M
2
EAR
Eargo, Inc. Common Stock
EAR
+$37.9M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$37.2M
4
SPRB
Spruce Biosciences
SPRB
+$36M
5
LUNG icon
Pulmonx
LUNG
+$24.5M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$135M
2
CNC icon
Centene
CNC
+$37.5M
3
BAX icon
Baxter International
BAX
+$27.2M
4
ASMB icon
Assembly Biosciences
ASMB
+$24.1M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 92.97%
2 Consumer Staples 1.52%
3 Consumer Discretionary 0.76%
4 Industrials 0.46%
5 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
76
Rocket Pharmaceuticals
RCKT
$384M
$22M 0.47%
+400,370
New +$14.6M
ACCD
77
DELISTED
Accolade Inc
ACCD
$21.8M 0.46%
500,000
+175,000
+54% +$7.77M
AMRN
78
Amarin Corp
AMRN
$301M
$20.5M 0.44%
209,750
-7,750
-4% -$747K
CHRS icon
79
Coherus Oncology
CHRS
$192M
$20.2M 0.43%
1,162,500
-502,949
-30% -$8.95M
ABCM
80
DELISTED
Abcam PLC
ABCM
$19.9M 0.42%
+925,000
New +$18M
PPD
81
DELISTED
PPD, Inc. Common Stock
PPD
$18M 0.38%
525,000
– –
GMDA
82
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$17.6M 0.37%
2,094,000
+77,344
+4% +$523K
ACRS icon
83
Aclaris Therapeutics
ACRS
$866M
$17.3M 0.37%
2,676,100
+599,793
+29% +$2.53M
INZY
84
DELISTED
Inozyme Pharma
INZY
$17.1M 0.36%
830,546
-49,408
-6% -$1.18M
RLAY icon
85
Relay Therapeutics
RLAY
$4.39B
$17.1M 0.36%
412,000
-1,674
-0.4% -$75.7K
RIGL icon
86
Rigel Pharmaceuticals
RIGL
$772M
$16.6M 0.35%
474,289
– –
KURA icon
87
Kura Oncology
KURA
$882M
$16.6M 0.35%
+508,116
New +$17.9M
CERE
88
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$16.6M 0.35%
+999,000
New +$13M
LKFT
89
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$16.3M 0.35%
165,000
-10,000
-6% -$1.22M
XENT
90
DELISTED
Intersect ENT, Inc
XENT
$16M 0.34%
700,000
+200,000
+40% +$3.81M
TARA icon
91
Protara Therapeutics
TARA
$220M
$15.6M 0.33%
643,200
-422
-0.1% -$9.1K
RYTM icon
92
Rhythm Pharmaceuticals
RYTM
$8.04B
$14.6M 0.31%
490,339
+26,253
+6% +$667K
JAZZ icon
93
Jazz Pharmaceuticals
JAZZ
$16.6B
$14.4M 0.31%
87,500
+30,000
+52% +$4.47M
MYOV
94
DELISTED
Myovant Sciences Ltd.
MYOV
$14.2M 0.3%
515,000
+2,289
+0.4% +$44.6K
APLT
95
DELISTED
Applied Therapeutics
APLT
$14M 0.3%
635,837
-355,736
-36% -$7.41M
GWPH
96
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$13.8M 0.29%
119,188
– –
CGEN icon
97
Compugen
CGEN
$228M
$13.7M 0.29%
1,133,600
+825
+0.1% +$11.4K
PRTA icon
98
Prothena Corp
PRTA
$471M
$13.7M 0.29%
1,141,100
+115,893
+11% +$1.37M
AKRO
99
DELISTED
Akero Therapeutics
AKRO
$13.3M 0.28%
515,371
+92,331
+22% +$2.57M
KNTE
100
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$12.9M 0.27%
+324,686
New +$13M
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Rock Springs Capital Management held 169 positions worth $4.72B, up 20% from $3.94B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Rock Springs Capital Management's Q4 2020 filing shows 21 new, 56 increased, 46 reduced and 14 closed positions. Its largest new stake was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M. The largest sale was Immunomedics Inc, an estimated $135M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,697,403 shares worth $70.9M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q4 2020, an estimated $37.2M increase.
  • Rock Springs Capital Management's biggest Q4 2020 reduction was Centene, cutting an estimated $37.5M.
  • Rock Springs Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $135M.
  • Rock Springs Capital Management's ten largest holdings make up 24% of its $4.72B portfolio in Q4 2020.
  • Rock Springs Capital Management opened 21 new positions and closed 14 in Q4 2020.
  • Rock Springs Capital Management's portfolio value rose 20% quarter-over-quarter to $4.72B.

Based on Rock Springs Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.